Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHuang, Min
dc.contributor.authorHaiderali, Amin
dc.contributor.authorFox, Grace E.
dc.contributor.authorFrederickson, Andrew
dc.contributor.authorCortés Castan, Javier
dc.contributor.authorFasching, Peter A.
dc.contributor.authorO’Shaughnessy, Joyce
dc.date.accessioned2022-09-09T07:21:15Z
dc.date.available2022-09-09T07:21:15Z
dc.date.issued2022-05
dc.identifier.citationHuang M, Haiderali A, Fox GE, Frederickson A, Cortes J, Fasching PA, et al. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. Pharmacoeconomics. 2022 May;40:519–58.
dc.identifier.issn1179-2027
dc.identifier.urihttp://hdl.handle.net/11351/8084
dc.descriptionTriple-Negative Breast Cancer; Economic burden
dc.description.abstractBackground Triple-negative breast cancer (TNBC) accounts for 10–20% of all breast cancers (BCs). It is more commonly diagnosed in younger women and often has a less favorable prognosis compared with other BC subtypes. Objective The objective of this study was to provide a literature-based extensive overview of the economic and humanistic burden of TNBC to assist medical decisions for healthcare payers, providers, and patients. Methods A systematic literature review was performed using multiple databases, including EMBASE, MEDLINE, Econlit, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from database inception to 16 May 2021. In addition, a targeted search was performed in the Northern Light Life Sciences Conference Abstracts database from 2016 through June 2021. The bibliographies of included articles were reviewed to identify other potentially relevant publications. Quality assessment of the included studies was conducted. Results The review identified 19 studies assessing the economic burden and 10 studies assessing the humanistic burden of TNBC. Studies varied widely in study design, settings, patient populations, and time horizons. The estimates of mean per-patient annual direct medical costs ranged from around $20,000 to over $100,000 in stage I–III TNBC and from $100,000 to $300,000 in stage IV TNBC. Healthcare costs and resource utilization increased significantly with disease recurrence, progression, and increased cancer stage or line of therapy. Compared with the costs of systemic anticancer therapy, cancer management costs comprised a larger portion of total direct costs. The estimates of indirect costs due to productivity loss ranged from $207 to $1573 per patient per month (all costs presented above were adjusted to 2021 US dollars). Cancer recurrence led to significantly reduced productivity and greater rates of leaving the workforce. A rapid deterioration of health utility associated with disease progression was observed in TNBC patients. Treatment with pembrolizumab or talazoparib showed significantly greater improvements in health-related quality of life (HRQoL) compared with chemotherapy, as measured by EORTC QLQ-C30, QLQ-BR23, and FACT-B. Conclusion TNBC is associated with a substantial economic burden on healthcare systems and societies and considerably reduced productivity and HRQoL for patients. This study synthesized the published literature on the economic and humanistic burden of TNBC and highlighted the need for continued research due to the rapidly changing landscape of TNBC care.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesPharmacoEconomics;40
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectAssistència sanitària - Cost
dc.subjectMama - Càncer - Tractament
dc.subject.meshTriple Negative Breast Neoplasms
dc.subject.mesh/therapy
dc.subject.meshHealth Care Costs
dc.titleEconomic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s40273-021-01121-7
dc.subject.decsneoplasias de mama triple negativos
dc.subject.decs/terapia
dc.subject.decscostes de la atención a la salud
dc.relation.publishversionhttps://doi.org/10.1007/s40273-021-01121-7
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Huang M, Haiderali A] Merck & Co., Inc., Kenilworth, NJ, USA. [Fox GE, Frederickson A] PRECISIONheor, New York, NY, USA. [Cortes J] International Breast Cancer Center (IBCC), Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Fasching PA] Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen, EMN, University Hospital Erlangen, Friedrich-Alexander University Erlangen, Nuremberg, Erlangen, Germany. [O'Shaughnessy J] Baylor University Medical Center, Texas Oncology and US Oncology, Dallas, TX, USA
dc.identifier.pmid35112331
dc.identifier.wos000750590800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record